Search Results - "Roca, C. Gomez"

Oral lichenoid reactions associated with anti‐PD‐1/PD‐L1 therapies: clinicopathological findings by Sibaud, V., Eid, C., Belum, V.R., Combemale, P., Barres, B., Lamant, L., Mourey, L., Gomez‐Roca, C., Estilo, C.L., Motzer, R., Vigarios, E., Lacouture, M.E.

Get full text

Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors by Vigarios, E., Lamant, L., Delord, J.P., Fricain, J.C., Chevreau, C., Barrés, B., Gomez-Roca, C., Boulanger, M., Sibaud, V.

Get full text

Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study by Charton, E., Baldini, C., Fayet, Y., Schultz, E., Auroy, L., Vallier, E., Italiano, A., Robert, M., Coquan, E., Isambert, N., Moreau, P., Touzeau, C., Le Tourneau, C., Ghrieb, Z., Kiladjian, J.-J., Delord, J.-P., Gomez Roca, C., Vey, N., Barlesi, F., Lesimple, T., Penel, N., Soria, J.-C., Massard, C., Besle, S.

“…Investigation of the disparities in the access to experimental treatment in early-phase clinical trials is lacking. The objective of the EGALICAN-2 study was…”
Get full text

Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety by Gomez-Roca, C.A., Lacroix, L., Massard, C., De Baere, T., Deschamps, F., Pramod, R., Bahleda, R., Deutsch, E., Bourgier, C., Angevin, E., Lazar, V., Ribrag, V., Koscielny, S., Chami, L., Lassau, N., Dromain, C., Robert, C., Routier, E., Armand, J.P., Soria, J.-C.

“…Sequential tumour biopsies are of potential interest for the rational development of molecular targeted therapies. From June 2004 to July 2009, 186 patients…”
Get full text

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal by Ott, P.A., Piha-Paul, S.A., Munster, P., Pishvaian, M.J., van Brummelen, E.M.J., Cohen, R.B., Gomez-Roca, C., Ejadi, S., Stein, M., Chan, E., Simonelli, M., Morosky, A., Saraf, S., Emancipator, K., Koshiji, M., Bennouna, J.

“…Safety and efficacy of pembrolizumab, a humanized programmed death 1 monoclonal antibody, was assessed in KEYNOTE-028, a multicohort, phase Ib trial for…”
Get full text

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages by Gomez-Roca, C.A., Italiano, A., Le Tourneau, C., Cassier, P.A., Toulmonde, M., D’Angelo, S.P., Campone, M., Weber, K.L., Loirat, D., Cannarile, M.A., Jegg, A.-M., Ries, C., Christen, R., Meneses-Lorente, G., Jacob, W., Klaman, I., Ooi, C.-H., Watson, C., Wonde, K., Reis, B., Michielin, F., Rüttinger, D., Delord, J.-P., Blay, J.-Y.

“…Emactuzumab is a monoclonal antibody against the colony-stimulating factor-1 receptor and targets tumor-associated macrophages (TAMs). This study assessed the…”
Get full text

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring by Gyawali, B., de Vries, E.G.E., Dafni, U., Amaral, T., Barriuso, J., Bogaerts, J., Calles, A., Curigliano, G., Gomez-Roca, C., Kiesewetter, B., Oosting, S., Passaro, A., Pentheroudakis, G., Piccart, M., Roitberg, F., Tabernero, J., Tarazona, N., Trapani, D., Wester, R., Zarkavelis, G., Zielinski, C., Zygoura, P., Cherny, N.I.

“…The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated, widely used tool developed to score the clinical…”
Get full text

Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase by Isambert, N., Delord, J.-P., Soria, J.-C., Hollebecque, A., Gomez-Roca, C., Purcea, D., Rouits, E., Belli, R., Fumoleau, P.

“…The second-generation oral heat shock protein inhibitor Debio0932 showed almost linear pharmacokinetics and some clinical activity along with manageable…”
Get full text

VOTRAGE study pazopanib in a population of “frail” elderly patients after geriatric assessment: A phase I study with geriatric criteria by Mourey, L., Ravaud, A., Digue, L., Cabarrou, B., Gomez-Roca, C.A., Valentin, T., Olivier, P., Fabre, A., Mounier, M., Balardy, L., Filleron, T.

Get full text

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours by Hollebecque, A, Bahleda, R, Faivre, L, Adam, J, Poinsignon, V, Paci, A, Gomez-Roca, C, Thery, J.C, Le Deley, M.C, Varga, A, Gazzah, A, Ileana, E, Gharib, M, Angevin, E, Malekzadeh, K, Massard, C, Soria, J.C, Spano, J.P

“…Abstract Background Preclinical studies suggest synergistic antitumour effects of mammalian target of rapamycin (mTOR) inhibitor such as temsirolimus combined…”
Get full text

First-in-human trial design for W0101: A first-in-class antibody-drug conjugate targeting IGF-1R and identification of the target patient population by Gomez-Roca, C A, Garralda-Cabanas, E, Cruzalegui, F, Ausseil, F, Zorza, G, Delfour, O, Besse, J, Akla, B, Gautier, S, Adam, J, Lacroix-Triki, M, Passioukov, A, Roche, R, Pavlyuk, M, Massard, C

Get full text

Clinical activity, safety, and PK/PD from a phase I study of RO6874281, a fibroblast activation protein (FAP) targeted interleukin-2 variant (IL-2v) by Melero, I, Castanon Alvarez, E, Mau-Sorensen, M, Lassen, U N, Lolkema, M P, Robbrecht, D G, Gomez-Roca, C A, Martin-Liberal, J, Tabernero, J, Ros, W, Ahmed, S, Isambert, N, Piper Lepoutre, H, Boetsch, C, Charo, J, Evers, S, Teichgräber, V, Schellens, J H M

Get full text

Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study by Baldini, C., Charton, E., Schultz, E., Auroy, L., Italiano, A., Robert, M., Coquan, E., Isambert, N., Moreau, P., Le Gouill, S., Le Tourneau, C., Ghrieb, Z., Kiladjian, J.J., Delord, J.P., Roca, C. Gomez, Vey, N., Barlesi, F., Lesimple, T., Penel, N., Soria, J.C., Massard, C., Besle, S.

“…Access to clinical trials and especially early-phase trials (ECT) is an important issue in geriatric oncology. As cancer can be considered an age-related…”
Get full text

Treatment of patients with brain metastases from a melanoma by Modesto, A, Chira, C, Sol, J-C, Lubrano, V, Boulinguez, S, Pagès, C, Sibaud, V, Gomez-Roca, C, Moyal, É, Meyer, N

“…Whereas immune checkpoint inhibitors of serine/threonine protein kinase B-raf therapy dramatically changed metastatic outcomes of patients with melanoma, they…”
Get full text

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma by Blay, J.Y., Cropet, C., Mansard, S., Loriot, Y., De La Fouchardière, C., Haroche, J., Topart, D., Tougeron, D., You, B., Italiano, A., Le Brun-Ly, V., Ferrero, J.M., Penel, N., Fabbro, M., Troussard, X., Malka, D., Ray-Coquard, I., Leboulleux, S., Fléchon, A., Maubec, E., Charles, J., Dalle, S., Taieb, S., Garcia, G.C.T.E., Mandache, A.M., Colignon, N., Gavrel, M., Nowak, F., Hoog Labouret, N., Mahier Aït Oukhatar, C., Gomez-Roca, C.

“…BRAF inhibitors are approved in BRAFV600-mutated metastatic melanoma, non-small-cell lung cancer (NSCLC), Erdheim–Chester disease (ECD), and thyroid cancer. We…”
Get full text

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database by Cassier, P.A., Polivka, V., Judson, I., Soria, J.-C., Penel, N., Marsoni, S., Verweij, J., Schellens, J.H., Morales-Barrera, R., Schöffski, P., Voest, E.E., Gomez-Roca, C., Evans, T.R.J., Plummer, R., Gallerani, E., Kaye, S.B., Olmos, D.

“…Although sarcomas account for only 1% of all solid tumours, patients with sarcomas comprise a larger proportion of patients entering phase I trials, due to the…”
Get full text

500 Pembrolizumab (MK-3475) for PD-L1-positive squamous cell carcinoma (SCC) of the anal canal: Preliminary safety and efficacy results from KEYNOTE-028 by Ott, P.A, Piha-Paul, S.A, Munster, P, Pishvaian, M.J, Van Brummelen, E, Cohen, R, Gomez-Roca, C, Ejadi, S, Stein, M, Chan, E, Simonelli, M, Morosky, A, Yuan, S.S, Koshiji, M, Bennouna, J

Get full text

502 Pembrolizumab (MK-3475) for patients (pts) with advanced colorectal carcinoma (CRC): Preliminary results from KEYNOTE-028 by O'Neil, B.H, Wallmark, J, Lorente, D, Elez, E, Raimbourg, J, Gomez-Roca, C, Ejadi, S, Piha-Paul, S.A, Moss, R.A, Siu, L.L, Dotti, K, Santoro, A, Gould, M, Yuan, S.S, Koshiji, M, Han, S.W

Get full text

308 Phase I of axitinib and everolimus in metastatic solid tumors and extension to metastatic renal cell carcinoma (mrcc): Results of EVAX study by Ravaud, A, Gomez-roca, C, Picat, M.Q, Digue, L, Chevreau, C, Gimbert, A, Chauzit, E, Asselineau, J, Cornelis, F, Sitta, R, Aziza, R, Daste, A, Bikfalvi, A, Pedenon-perichout, D, Doussau, A, Molimard, M, Delord, J.P

Get full text

SP-0598: Cilengitide in continuous infusion with radio-chemotherapy in stage III NSCLC: A phase I clinical trial by Cohen-Jonathan Moyal, E, Massabeau, C, Filleron, T, Modesto, A, Bachaud, J.M, Rouquette, I, Dierickx, L, Aziza, R, Bigay-Game, L, Plat, G, Mounier, M, Gomez-Roca, C, Delord, J.P, Mazieres, J

Get full text